Paclitaxel protein-bound

Phase 2Small molecule

Paclitaxel protein-bound is one of 116 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

115

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

Pancreatic Ductal AdenocarcinomaActive, not recruiting

Pancreatic CancerActive, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

Pancreatic Ductal AdenocarcinomaPhase 2

Active, not recruiting

Pancreatic CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Preclinical

108 2

Paclitaxel protein-bound

HHonorHealth Research Institute

Phase 2

2 3

Medrol

Pfizer

Preclinical

1 4

Byetta

AstraZeneca

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

ABI-007

Bristol-Myers Squibb

Preclinical

2 7

Chemotherapy Agents

Takeda

Preclinical

1 8

Active Comparator

Moderna

Preclinical

1 9

LDE225

Novartis

Preclinical

1 10

Sulfonylureas

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Not yet recruiting

Nasopharyngeal Carcinoma

NCT06331845

Clinical

Trials by Indication[1]

Pancreatic Cancer2 trials

High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Withdrawn·MMedical College of Wisconsin·Phase 1/2·NCT03908333

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Withdrawn·HHitendra Patel·Phase 1/2·NCT03697239

Pancreas Cancer1 trial

Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer

Active, not recruiting·HHonorHealth Research Institute·Phase 2·NCT04669197·19 enrolled

Nasopharyngeal Carcinoma1 trial

Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT06331845·39 enrolled

Ascorbic Acid1 trial

Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)

Completed·HHonorHealth Research Institute·Phase 1/2·NCT03410030·27 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Completed·BBarts & The London NHS Trust·Phase 2·NCT04054362·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Paclitaxel protein-bound. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Paclitaxel protein-bound compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Paclitaxel protein-bound. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HonorHealth Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHonorHealth Research Institute

Paclitaxel protein-bound

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Pancreatic Cancer2 trials

Pancreas Cancer1 trial

Nasopharyngeal Carcinoma1 trial

Ascorbic Acid1 trial

Pancreatic Ductal Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News